Topic

Articles

Cytiva and Pall reinforce recent expansion efforts with a $1.5-billion dollar investment in new manufacturing facilities.

Cytiva and Pall Investing $1.5 Billion into Manufacturing Expansion

Meissa Vaccines’s MV-014-212, an intranasal recombinant live attenuated COVID-19 vaccine, induced mucosal and systemic antibodies against SARS-CoV-2 and two variants of concern.

Meissa’s Intranasal COVID-19 Vaccine Yields Promising Preclinical Data

Kadmon Pharmaceuticals selects Onco360 to be a specialty pharmacy partner for Rezurock (belumosudil).

Kadmon Pharmaceuticals Partners with Oncology Pharmacy for New Chronic Graft-Versus-Host Disease Therapy

The companies collaborate to develop and commercialize ARV-471, an investigational oral PROTAC (proteolysis targeting chimeras) estrogen receptor protein degrader.

Pfizer and Arvinas to Develop and Commercialize Estrogen Receptor Targeting Breast Cancer 

Exscientia and GT Apeiron Therapeutics have entered into a strategic R&D oncology collaboration agreement.

Exscientia and GT Apeiron Form Strategic R&D Collaboration Agreement

Catalent commences the first phase of a $100-million expansion program Anagni site to increase its manufacturing capabilities for biologics drug substance.

Catalent Invests $100 Million to Expand European Biologics Manufacturing Capabilities

Samsung Biologics and Kineta have entered into a strategic partnership for drug product manufacturing services and to support an IND filing of a novel antibody therapeutic. 

Samsung Biologics Partners with Kineta for Anti-VISTA Antibody Immunotherapy

BioNTech will acquire a TCR cell therapy R&D platform as well as a manufacturing facility in Gaithersburg, Md., from Kite, a Gilead company. 

BioNTech to Acquire Kite’s TCR Cell Therapy Platform and Manufacturing Facility

Cellares has entered into a strategic relationship with Poseida Therapeutics to advance a closed, automated, and scalable cell therapy manufacturing system.

Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy Manufacturing

Pall has secured a manufacturing contract with Exothera for the suspension-based manufacture of gene therapies and viral vector-based vaccines.

Deals, Development and Manufacturing